TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04530487

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lapine T-Lymphocyte Immune Globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study: NCT02383888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Study: NCT04629391

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total shoulder arthroplasty
Description: A prosthesis (either anatomic or reverse) will be implanted in shoulders patients that suffer from primary glenohumeral arthritis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total shoulder arthroplasty
Description: A prosthesis (either anatomic or reverse) will be implanted in shoulders patients that suffer from primary glenohumeral arthritis.
Study: NCT02494973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin HAI
Description: Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin IV
Description: Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LV5FU2
Description: Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
Study: NCT03103321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT01910324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional Family Therapy Cross-Systems
Description: Standard initial/engagement work in the home and detention, plus a state-of-the-art HIV education prevention module as well as standard MDFT which assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Services as Usual
Description: Standard drug treatment services in detention and state-of-the-art HIV education prevention intervention, as well as outpatient drug treatment provided by community drug treatment providers
Study: NCT03775265

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection of Bladder Tumor
Description: Undergo a TURBT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder Tumor
Description: Undergo a TURBT
Study: NCT02635113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait Synchronized Vibration System
Description: A wearable vibratory shoe that delivers stimulus to the soles that is synchronized with step resulting in improved gait.The shoe consists of two externally mounted vibration units (tactors). The vibration units allow for variation of both frequency and amplitude of stimulation independently. Using the pressure sensors and timing data, gait velocity, cadence, swing time, stance phase and double support time will be analyzed to assess features of their gait performance during the Dynamic Gait Index with and without vibratory stimuli.
Study: NCT03067597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: The DVI contains 10 mg dinoprostone
Study: NCT00044304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: The dosing regimen to be used initially (400 mg po qd in adults and 260 mg/m2/day in children with food and a glass of water) is identical to that recommended by the FDA for the treatment of the chronic phase of chronic myelogenous leukemia (CML) (Prod Info Gleevec ). In patients with ANC \<1500/mm3, platelet counts \< 75,000mm3 or abnormal liver function tests (ALT or AST \> 2.5 or bilirubin \> 3 times the upper limit of normal), the starting dose will be reduced to 300 mg po qD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: The dosing regimen to be used initially (15 mg po bid) is identical to that recommended by the FDA for the treatment of myelofibrosis with platelet counts of 100-200,000/mm3 (Prod Info ruxolitinib). In patients with platelet counts \<100,000/mm3, moderate renal impairment (CrCl \<60 mL/min) or abnormal liver function tests (ALT or AST \> 2.5 or bilirubin \> 3 times the upper limit of normal), the starting dose will be reduced to 10 mg bid. The recommended guidelines for dose adjustment during therapy and discontinuation of therapy in myelofibrosis will be followed.
Study: NCT03281603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM complete denture
Description: complete denture will be designed by computer aided designing (CAD) and manufactured by computer aided manufacturing(CAM) utilizing Milling and 3D printing techniques

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD/CAM complete denture
Description: complete denture will be designed by computer aided designing (CAD) and manufactured by computer aided manufacturing(CAM) utilizing Milling and 3D printing techniques
Study: NCT05421117

Intervention type: PROCEDURE
Intervention: Laparoscopic adnexal mass extraction
Description: Compared with open procedures, Minimally invasive surgery (MIS) is associated with faster recovery times, better patient quality of life, and lower postoperative complication rates. The removal of an adnexal mass from the abdominal cavity is performed most commonly using the suprapubic, trans umbilical (TU), or trans vaginal (TV) route.
Study: NCT03529305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Receive rTMS treatment to the primary motor cortex (M1)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Receive rTMS treatment to the primary motor cortex (M1)
Study: NCT00493324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyvalent pneumococcal vaccine
Description: Injection
Study: NCT03529305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Receive physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Receive physical therapy
Study: NCT00559455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200mg/m², Day 1 and Day 2; Every 2 weeks
Study: NCT03529305

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Receive physical therapy
Study: NCT01664741

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch - transdermal
Description: 21 mg patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04178525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ChitoCare gel
Description: ChitoCare gel is based on chitosan and used as an addition to standard care, accordingly with dressing change for 10 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Placebo gel is used as an addition to standard care, accordingly with dressing change for 10 weeks.
Study: NCT04047706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 Inhibitor BMS-986205 25mg
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 Inhibitor BMS-986205 50 mg
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDO1 Inhibitor BMS-986205 100 mg
Description: Given PO
Study: NCT03563742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine 25 mg
Description: Participants will receive rilpivirine 25 mg tablet orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate (TDF)/Lamivudine (3TC)
Description: Participants will receive 1 fixed dose combination tablet once daily containing 300 mg TDF and 300 mg 3TC.
Study: NCT03193970

Intervention type: BEHAVIORAL
Intervention: Post-Operative Recovery Registry
Description: Multi-institutional prospective database of patients with bladder cancer undergoing radical cystectomy.
Study: NCT03722420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radotinib
Description: Patients randomized to the radotinib arms will receive 300 mg of radotinib BID (1 in the morning and 1 in the evening, at approximately 12-hour intervals).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Patients randomized to the imatinib 400 mg arm will receive imatinib once a day throughout the study.
Study: NCT03284827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOAC
Description: edoxaban (60 mg once daily \[OD\]) for at least 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DAPT
Description: clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months
Study: NCT03777878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: 100 μg carbetocin ampoule will be diluted in 10 mL normal saline and administered slowly (over 30-60 s) intravenously by the anesthetist after the birth of the baby
Study: NCT02013115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation
Study: NCT02605850

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: All subjects will consume ground beef patty meal with water at the baseline visit.
Study: NCT03103321

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03394066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS (MagVenture MagPro 100 with MagOption)
Description: TMS will be applied using the MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) stimulator with a figure-of-eight TMS coil. An MRI compatible version of the figure-of-eight coil will be used inside the MRI scanner with an appropriate TMS coil holder.
Study: NCT04415060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane Inhalant Product
Description: Isoflurane will be administered using an inhalation device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane inhalant product
Description: Sevoflurane will be administered using an inhalation device
Study: NCT03538652

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: JITAI
Description: Just-In-Time Adaptive Intervention delivered via smartphone app

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02605850

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate Juice
Description: Pomegranate Juice will be taken 1/day for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pomegranate extract
Description: Pomegranate extract will be taken 1/day for 4 weeks.
Study: NCT02867956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles
Study: NCT01583868

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B&L RD2135-01 lens C
Description: Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B&L RD2135-01 lens D
Description: Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PureVision2
Description: Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua
Description: Lenses will be worn on a daily wear basis for 1 week. Lens care solution and lens cases will be provided for daily rinsing, cleaning, disinfecting, and storing the lenses. Rewetting drops will be provided for use as needed during the study.
Study: NCT04132154

Intervention type: PROCEDURE
Intervention: Convective Forced-Air Active Warming
Description: Underbody Blanket Model 585 of the 3M BairHugger Series
Study: NCT00474799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNS075
Description: MNS075 7.5mg q1h MNS075 15mg q3h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNS075
Description: MNS075 7.5mg q1h MNS075 15mg q3h
Study: NCT02205515

Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus
Description: Everolimus is a novel derivative of rapamycin.
Study: NCT03388840

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose derived stem cells suspention
Description: application of adipose derived stem cells to the engrafted hair in hair transplantation surgery

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma
Description: application of autologous platelet rich plasma to the engrafted hair in hair transplantation surgery
Study: NCT04516226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaginal cleansing with chlorhexidine gluconate solution
Description: Cleansing of the vaginal walls with chlorhexidine gluconate solution for women diagnosed with PPROM
Study: NCT04178421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized training program
Description: Eye-gaze fixation computer based training program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pac-Man, Zookeeper, Tetris
Study: NCT02220452

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music listening during anesthesia
Description: In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: absence of music listening during anesthesia
Description: In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
Study: NCT02977832

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Odyliresin
Description: Odyliresin 2 ml, 20 drops once daily and alpha-antagonist (alfuzosin 10 mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Odyliresin
Description: Odyliresin 2 ml, 20 drops once daily and alpha-antagonist (alfuzosin 10 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: 10Mg Oral Tablet, Extended Release

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Description: 10Mg Oral Tablet, Extended Release
Study: NCT02502526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centurion® Vision System, 45° Balanced Tip

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Centurion® Vision System, 45° MFK Tip

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lnfiniti® Vision System, 45° MFK Tip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INTREPID® Ultra infusion sleeve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INTREPID® Ultra infusion sleeve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultra infusion sleeve
Study: NCT02160119

Intervention type: OTHER
Intervention: MRI-based techniques
Description: fMRI, DTI

Intervention type: OTHER
Intervention: MRI-based techniques
Description: fMRI, DTI

Intervention type: OTHER
Intervention: EEG
Description: ERP

Intervention type: OTHER
Intervention: EEG
Description: ERP
Study: NCT04455204

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum asymmetteric dimethyl arginine
Description: Serum asymmetteric dimethyl arginine (ADMA) will be done using Enzyme-Linked Immunosorbent Assay

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum asymmetteric dimethyl arginine
Description: Serum asymmetteric dimethyl arginine (ADMA) will be done using Enzyme-Linked Immunosorbent Assay

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum asymmetteric dimethyl arginine
Description: Serum asymmetteric dimethyl arginine (ADMA) will be done using Enzyme-Linked Immunosorbent Assay

Intervention type: DIAGNOSTIC_TEST
Intervention: serum lipid profiles
Description: serum lipid profiles including triglycerides (TG), total cholesterol and high-density lipoprotein cholesterol (HDL-C) which will be measured by enzymatic colorimetric method) using commercial kits

Intervention type: DIAGNOSTIC_TEST
Intervention: serum lipid profiles
Description: serum lipid profiles including triglycerides (TG), total cholesterol and high-density lipoprotein cholesterol (HDL-C) which will be measured by enzymatic colorimetric method) using commercial kits

Intervention type: DIAGNOSTIC_TEST
Intervention: serum lipid profiles
Description: serum lipid profiles including triglycerides (TG), total cholesterol and high-density lipoprotein cholesterol (HDL-C) which will be measured by enzymatic colorimetric method) using commercial kits

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum vaspin
Description: vaspin concentrations will be assayed using commercially available ELISA kits

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum vaspin
Description: vaspin concentrations will be assayed using commercially available ELISA kits

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum vaspin
Description: vaspin concentrations will be assayed using commercially available ELISA kits

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum resistin
Description: resistin concentrations will be assayed using commercially available ELISA kits

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum resistin
Description: resistin concentrations will be assayed using commercially available ELISA kits

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum resistin
Description: resistin concentrations will be assayed using commercially available ELISA kits
Study: NCT01957332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Molecular imaging
Description: On the day of FES-injection\&scan or the day after FES-injection, 89Zr-trastuzumab (\~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Molecular imaging
Description: All patients receive 18F-FES (\~200MBq) injection followed by a FES-PET.
Study: NCT03783416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib (NINLARO®) capsules / Matching placebo capsules
Description: Participants will be treated for a maximum of 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixazomib (NINLARO®) capsules / Matching placebo capsules
Description: Participants will be treated for a maximum of 24 months